Miriam Annett

Miriam Annett

Auto-generated profile, based on publicly available information

Miriam Annett

Radius Health Inc, Boston, MA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2021 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
PMPaul D. Miller
Paul D. Miller
STSteven Troy
Steven Troy
RWRichard J. Weiss
Richard J. Weiss
MAMiriam Annett
Miriam Annett
JSJason Schense
Jason Schense
BMBruce Mitlak
Bruce Mitlak
Background and Objective Abaloparatide, an anabolic osteoporosis treatment administered by subcutaneous (SC) injection, increases bone mineral density (BMD) and reduces fracture risk in postmenopausal women with osteoporosis. The abaloparatide-solid Microstructured Transdermal System [abaloparatide-sMTS (Kindeva, St Paul, MN, USA)], which delivers abaloparatide intradermally, is in development to provide an alternative method for abaloparatide delivery. The objective of this study was to evaluate the ability of subjects to self-administer abaloparatide-sMTS, based on pharmacokinetic and pharmacodynamic markers. Methods In this single-arm, open-label, Phase 1b study, 22 healthy postmenopausal women aged 50–85 years with low BMD were trained to self-administer abaloparatide-sMTS 300 μg once daily to the thigh for 5 min for 29 days. The primary endpoint was systemic exposure to abaloparatide. Secondary endpoints included percent change from baseline in serum procollagen type I N-terminal propeptide (s-PINP), patient experience, and safety. Results All 22 subjects completed the study. At baseline, mean age was 65.2 years, mean total hip T-score was − 1.32, and mean lumbar spine T-score was − 1.98. On Day 1, the median time to reach maximum concentration (Tmax) for abaloparatide-sMTS was 0.33 h and geometric mean (CV %) maximum concentration (Cmax) and area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0–t) were 447 (38.0) pg/mL and 678 (45.3) pg·h/mL, respectively; the pharmacokinetic profile was similar on Days 15 and 29. Median percentage change in s-PINP was 45.4% and 64.4% at Days 15 and 29, respectively. The most common adverse events (AEs) were application site erythema, pain, and swelling, which were mostly of mild or moderate severity. No AEs led to study drug withdrawal and no serious AEs were reported. The success rate for self-administration at first application was 99.7%, and subject acceptability was high (~ 4.5 on a 5-point Likert Scale). Conclusions Subjects successfully self-administered abaloparatide-sMTS, which provided a consistent pharmacokinetic profile over 29 days and produced s-PINP increases from baseline similar to that observed in the pivotal trial with abaloparatide-SC. Observed patient experience along with the clinical data support continued clinical development of abaloparatide-sMTS. Trial Registration Number NCT04366726, Date of registration 04/29/2020, retrospectively registered

1 January 2022 in Clinical Breast Cancer
Verified
Journal Article
Closed access
PLPatricia LoRusso
Patricia LoRusso
EHErika Hamilton
Erika Hamilton
Cynthia MaCynthia Ma
Cynthia Ma
NVNeelima Vidula
Neelima Vidula
RBRebecca G. Bagley
Rebecca G. Bagley
AWAmy Weise
Amy Weise

1 October 2016 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
IHIrene Hramiak
Irene Hramiak
AAAndrew Ahmann
Andrew Ahmann
MCMatthew Capethorn
Matthew Capethorn
GCGuillaume Charpentier
Guillaume Charpentier
FDFrancesco Dotta
Francesco Dotta
VAVanita R. Aroda
Vanita R. Aroda